Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Ann.Vasc.Surg
According to the terms of the agreement, Eli Lilly will obtain exclusive, target specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets
Original clinical trial protocol available at ClinicalTrials.gov NCT04019197
Khan FY, Kabiraj G, Ahmed MA, Adam M, Mannuru SP, Ramesh V, et al
Researchers should follow standard laboratory safety protocols when handling
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
